<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37500993</PMID><DateCompleted><Year>2023</Year><Month>08</Month><Day>31</Day></DateCompleted><DateRevised><Year>2023</Year><Month>09</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1759-4766</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>9</Issue><PubDate><Year>2023</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Nature reviews. Neurology</Title><ISOAbbreviation>Nat Rev Neurol</ISOAbbreviation></Journal><ArticleTitle>Nutritional and metabolic factors in amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>511</StartPage><EndPage>524</EndPage><MedlinePgn>511-524</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41582-023-00845-8</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is a complex neurodegenerative disease that is classically thought to impact the motor system. Over the past 20 years, research has started to consider the contribution of non-motor symptoms and features of the disease, and how they might affect ALS prognosis. Of the non-motor features of the disease, nutritional status (for example, malnutrition) and metabolic balance (for example, weight loss and hypermetabolism) have been consistently shown to contribute to more rapid disease progression and/or earlier death. Several complex cellular changes observed in ALS, including mitochondrial dysfunction, are also starting to be shown to contribute to bioenergetic failure. The resulting energy depletion in high energy demanding neurons makes them sensitive to apoptosis. Given that nutritional and metabolic stressors at the whole-body and cellular level can impact the capacity to maintain optimal function, these factors present avenues through which we can identify novel targets for treatment in ALS. Several clinical trials are now underway evaluating the effectiveness of modifying energy balance in ALS, making this article timely in reviewing the evidence base for metabolic and nutritional interventions.</AbstractText><CopyrightInformation>&#xa9; 2023. Springer Nature Limited.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ludolph</LastName><ForeName>Albert</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Ulm, Ulm, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Deutsches Zentrum f&#xfc;r Neurodegenerative Erkrankungen (DZNE), Site Ulm, Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dupuis</LastName><ForeName>Luc</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Universit&#xe9; de Strasbourg, Inserm, M&#xe9;canismes Centraux et P&#xe9;riph&#xe9;riques de la Neurod&#xe9;g&#xe9;n&#xe9;rescence, UMR-S1118, Centre de Recherches en Biom&#xe9;decine, Strasbourg, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kasarskis</LastName><ForeName>Edward</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Kentucky, Lexington, KY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Steyn</LastName><ForeName>Frederik</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>School of Biomedical Sciences, The University of Queensland, Brisbane, QLD, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ngo</LastName><ForeName>Shyuan</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-1388-2108</Identifier><AffiliationInfo><Affiliation>Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, Brisbane, QLD, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McDermott</LastName><ForeName>Christopher</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-1269-9053</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, University of Sheffield, Sheffield, UK. c.j.mcdermott@sheffield.ac.uk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>07</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Rev Neurol</MedlineTA><NlmUniqueID>101500072</NlmUniqueID><ISSNLinking>1759-4758</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="Y">Neurodegenerative Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004734" MajorTopicYN="N">Energy Metabolism</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>6</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>8</Month><Day>31</Day><Hour>6</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>7</Month><Day>28</Day><Hour>1</Hour><Minute>8</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>7</Month><Day>27</Day><Hour>23</Hour><Minute>35</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37500993</ArticleId><ArticleId IdType="doi">10.1038/s41582-023-00845-8</ArticleId><ArticleId IdType="pii">10.1038/s41582-023-00845-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hardiman, O. et al. Amyotrophic lateral sclerosis. Nat. Rev. Dis. Prim. 3, 17071, https://doi.org/10.1038/nrdp.2017.71 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrdp.2017.71</ArticleId><ArticleId IdType="pubmed">28980624</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Damme, P., Robberecht, W. &amp; Van Den Bosch, L. Modelling amyotrophic lateral sclerosis: progress and possibilities. Dis. Model. Mech. 10, 537&#x2013;549 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28468939</ArticleId><ArticleId IdType="pmc">5451175</ArticleId><ArticleId IdType="doi">10.1242/dmm.029058</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton, A. E., Chio, A. &amp; Traynor, B. J. State of play in amyotrophic lateral sclerosis genetics. Nat. Neurosci. 17, 17&#x2013;23 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24369373</ArticleId><ArticleId IdType="doi">10.1038/nn.3584</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton, A. E. et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 72, 257&#x2013;268 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21944779</ArticleId><ArticleId IdType="pmc">3200438</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2011.09.010</ArticleId></ArticleIdList></Reference><Reference><Citation>Muller, K. et al. Comprehensive analysis of the mutation spectrum in 301 German ALS families. J. Neurol. Neurosurg. Psychiatry 89, 817&#x2013;827 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29650794</ArticleId><ArticleId IdType="doi">10.1136/jnnp-2017-317611</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen, D. R. et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 362, 59&#x2013;62 (1993).</Citation><ArticleIdList><ArticleId IdType="pubmed">8446170</ArticleId><ArticleId IdType="doi">10.1038/362059a0</ArticleId></ArticleIdList></Reference><Reference><Citation>Kabashi, E. et al. TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis. Nat. Genet. 40, 572&#x2013;574 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18372902</ArticleId><ArticleId IdType="doi">10.1038/ng.132</ArticleId></ArticleIdList></Reference><Reference><Citation>Sreedharan, J. et al. TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science 319, 1668&#x2013;1672 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18309045</ArticleId><ArticleId IdType="pmc">7116650</ArticleId><ArticleId IdType="doi">10.1126/science.1154584</ArticleId></ArticleIdList></Reference><Reference><Citation>Vance, C. et al. Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science 323, 1208&#x2013;1211 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19251628</ArticleId><ArticleId IdType="pmc">4516382</ArticleId><ArticleId IdType="doi">10.1126/science.1165942</ArticleId></ArticleIdList></Reference><Reference><Citation>McCann, E. P. et al. Evidence for polygenic and oligogenic basis of Australian sporadic amyotrophic lateral sclerosis. J. Med. Genet. 58, 87&#x2013;95 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jmedgenet-2020-106866</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta, P. R. et al. The impact of age on genetic testing decisions in amyotrophic lateral sclerosis. Brain 145, 4440&#x2013;4447 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">36162820</ArticleId><ArticleId IdType="pmc">9762932</ArticleId><ArticleId IdType="doi">10.1093/brain/awac279</ArticleId></ArticleIdList></Reference><Reference><Citation>Shepheard, S. R. et al. Value of systematic genetic screening of patients with amyotrophic lateral sclerosis. J. Neurol. Neurosurg. Psychiatry 92, 510&#x2013;518 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33589474</ArticleId><ArticleId IdType="doi">10.1136/jnnp-2020-325014</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Chalabi, A. et al. Analysis of amyotrophic lateral sclerosis as a multistep process: a population-based modelling study. Lancet Neurol. 13, 1108&#x2013;1113 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">25300936</ArticleId><ArticleId IdType="pmc">4197338</ArticleId><ArticleId IdType="doi">10.1016/S1474-4422(14)70219-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Chio, A. et al. The multistep hypothesis of ALS revisited: the role of genetic mutations. Neurology 91, e635&#x2013;e642 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30045958</ArticleId><ArticleId IdType="pmc">6105040</ArticleId><ArticleId IdType="doi">10.1212/WNL.0000000000005996</ArticleId></ArticleIdList></Reference><Reference><Citation>Filippini, T. et al. Environmental and occupational risk factors of amyotrophic lateral sclerosis: a population-based case-control study. Int. J. Environ. Res. Public Health https://doi.org/10.3390/ijerph17082882 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijerph17082882</ArticleId><ArticleId IdType="pubmed">33419346</ArticleId><ArticleId IdType="pmc">7766088</ArticleId></ArticleIdList></Reference><Reference><Citation>Bradley, W. G., Miller, R. X., Levine, T. D., Stommel, E. W. &amp; Cox, P. A. Studies of environmental risk factors in amyotrophic lateral sclerosis (ALS) and a phase I clinical trial of L-serine. Neurotox. Res. 33, 192&#x2013;198 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">28527102</ArticleId><ArticleId IdType="doi">10.1007/s12640-017-9741-x</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, H. et al. Smoking and risk of amyotrophic lateral sclerosis: a pooled analysis of 5 prospective cohorts. Arch. Neurol. 68, 207&#x2013;213 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21320987</ArticleId><ArticleId IdType="pmc">3319086</ArticleId><ArticleId IdType="doi">10.1001/archneurol.2010.367</ArticleId></ArticleIdList></Reference><Reference><Citation>Boddy, S. L. et al. The gut microbiome: a key player in the complexity of amyotrophic lateral sclerosis (ALS). BMC Med. https://doi.org/10.1186/s12916-020-01885-3 (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12916-020-01885-3</ArticleId><ArticleId IdType="pubmed">33468103</ArticleId><ArticleId IdType="pmc">7816375</ArticleId></ArticleIdList></Reference><Reference><Citation>Julian, T. H. et al. Physical exercise is a risk factor for amyotrophic lateral sclerosis: convergent evidence from Mendelian randomisation, transcriptomics and risk genotypes. EBioMedicine 68, 103397 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34051439</ArticleId><ArticleId IdType="pmc">8170114</ArticleId><ArticleId IdType="doi">10.1016/j.ebiom.2021.103397</ArticleId></ArticleIdList></Reference><Reference><Citation>Desport, J. C. et al. Nutritional status is a prognostic factor for survival in ALS patients. Neurology 53, 1059&#x2013;1063 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10496266</ArticleId><ArticleId IdType="doi">10.1212/WNL.53.5.1059</ArticleId></ArticleIdList></Reference><Reference><Citation>Kasarskis, E. J., Berryman, S., Vanderleest, J. G., Schneider, A. R. &amp; McClain, C. J. Nutritional status of patients with amyotrophic lateral sclerosis: relation to the proximity of death. Am. J. Clin. Nutr. 63, 130&#x2013;137 (1996).</Citation><ArticleIdList><ArticleId IdType="pubmed">8604660</ArticleId><ArticleId IdType="doi">10.1093/ajcn/63.1.130</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Reilly, E. J. et al. Premorbid body mass index and risk of amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Frontotemporal Degener. 14, 205&#x2013;211 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23134505</ArticleId><ArticleId IdType="doi">10.3109/21678421.2012.735240</ArticleId></ArticleIdList></Reference><Reference><Citation>Charcot, J. &amp; Joffroy, A. Deux cas d&#x2019;atrophie musculaire progressive avec lesions de la substance grise et de faisceaux antero-lateraux de la moelle epiniere. Arch. Physiol. Norm. Pathol. 1, 354&#x2013;367 (1869).</Citation></Reference><Reference><Citation>Bensimon, G., Lacomblez, L. &amp; Meininger, V. ALS/Riluzole Study Group. A controlled trial of riluzole in amyotrophic lateral sclerosis. N. Engl. J. Med. 330, 585&#x2013;591 (1994).</Citation><ArticleIdList><ArticleId IdType="pubmed">8302340</ArticleId><ArticleId IdType="doi">10.1056/NEJM199403033300901</ArticleId></ArticleIdList></Reference><Reference><Citation>Amyotrophic Lateral Sclerosis/Riluzole Study Group II et al. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Lancet 347, 1425&#x2013;1431 (1996).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(96)91680-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Abe, K. et al. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 16, 505&#x2013;512 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(17)30115-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks, B. R. et al. Edaravone efficacy in amyotrophic lateral sclerosis with reduced forced vital capacity: post-hoc analysis of Study 19 (MCI186-19) [clinical trial NCT01492686]. PLoS ONE 17, e0258614 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35700157</ArticleId><ArticleId IdType="pmc">9197041</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0258614</ArticleId></ArticleIdList></Reference><Reference><Citation>Paganoni, S. et al. Effect of sodium phenylbutyrate/taurursodiol on tracheostomy/ventilation-free survival and hospitalisation in amyotrophic lateral sclerosis: long-term results from the CENTAUR trial. J. Neurol. Neurosurg. Psychiatry 93, 871&#x2013;875 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35577511</ArticleId><ArticleId IdType="doi">10.1136/jnnp-2022-329024</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller, T. M. et al. Trial of antisense oligonucleotide tofersen for SOD1 ALS. N. Engl. J. Med. 387, 1099&#x2013;1110 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">36129998</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa2204705</ArticleId></ArticleIdList></Reference><Reference><Citation>Vucic, S. et al. ALS is a multistep process in South Korean, Japanese, and Australian patients. Neurology 94, e1657&#x2013;e1663 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32071166</ArticleId><ArticleId IdType="pmc">7251515</ArticleId><ArticleId IdType="doi">10.1212/WNL.0000000000009015</ArticleId></ArticleIdList></Reference><Reference><Citation>Diekmann, K. et al. Impact of comorbidities and co-medication on disease onset and progression in a large German ALS patient group. J. Neurol. 267, 2130&#x2013;2141 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32266542</ArticleId><ArticleId IdType="doi">10.1007/s00415-020-09799-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Janse van Mantgem, M. R. et al. Prognostic value of weight loss in patients with amyotrophic lateral sclerosis: a population-based study. J. Neurol. Neurosurg. Psychiatry 91, 867&#x2013;875 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32576612</ArticleId><ArticleId IdType="doi">10.1136/jnnp-2020-322909</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei, Q. Q. et al. Early weight instability is associated with cognitive decline and poor survival in amyotrophic lateral sclerosis. Brain Res. Bull. 171, 10&#x2013;15 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33636227</ArticleId><ArticleId IdType="doi">10.1016/j.brainresbull.2021.02.022</ArticleId></ArticleIdList></Reference><Reference><Citation>Li, J. Y. et al. Correlation of weight and body composition with disease progression rate in patients with amyotrophic lateral sclerosis. Sci. Rep. https://doi.org/10.1038/s41598-022-16229-9 (2022).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-16229-9</ArticleId><ArticleId IdType="pubmed">36587113</ArticleId><ArticleId IdType="pmc">9803702</ArticleId></ArticleIdList></Reference><Reference><Citation>Kandler, K. et al. Phenotyping of the thoracic-onset variant of amyotrophic lateral sclerosis. J. Neurol. Neurosurg. Psychiatry 93, 563&#x2013;565 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">34667101</ArticleId><ArticleId IdType="doi">10.1136/jnnp-2021-326712</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia, K. et al. Mutation-specific metabolic profiles in presymptomatic amyotrophic lateral sclerosis. Eur. J. Neurol. 30, 87&#x2013;95 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">36169607</ArticleId><ArticleId IdType="doi">10.1111/ene.15584</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakayama, Y. et al. Body weight variation predicts disease progression after invasive ventilation in amyotrophic lateral sclerosis. Sci. Rep. 9, 12262 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31439899</ArticleId><ArticleId IdType="pmc">6706382</ArticleId><ArticleId IdType="doi">10.1038/s41598-019-48831-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Hesters, A. et al. Predictive factors for prognosis after gastrostomy placement in routine non-invasive ventilation users ALS patients. Sci. Rep. 10, 15117 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32934263</ArticleId><ArticleId IdType="pmc">7492246</ArticleId><ArticleId IdType="doi">10.1038/s41598-020-70422-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Marin, B. et al. Population-based evidence that survival in amyotrophic lateral sclerosis is related to weight loss at diagnosis. Neurodegener. Dis. 16, 225&#x2013;234 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26866503</ArticleId><ArticleId IdType="doi">10.1159/000442444</ArticleId></ArticleIdList></Reference><Reference><Citation>Marin, B. et al. Alteration of nutritional status at diagnosis is a prognostic factor for survival of amyotrophic lateral sclerosis patients. J. Neurol. Neurosurg. Psychiatry 82, 628&#x2013;634 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21097551</ArticleId><ArticleId IdType="doi">10.1136/jnnp.2010.211474</ArticleId></ArticleIdList></Reference><Reference><Citation>Dardiotis, E. et al. Body mass index and survival from amyotrophic lateral sclerosis: a meta-analysis. Neurol. Clin. Pract. 8, 437&#x2013;444 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30564498</ArticleId><ArticleId IdType="pmc">6276330</ArticleId><ArticleId IdType="doi">10.1212/CPJ.0000000000000521</ArticleId></ArticleIdList></Reference><Reference><Citation>Dorst, J. et al. Prognostic factors in ALS: a comparison between Germany and China. J. Neurol. 266, 1516&#x2013;1525 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30923935</ArticleId><ArticleId IdType="doi">10.1007/s00415-019-09290-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Witzel, S. et al. Fast versus slow disease progression in amyotrophic lateral sclerosis &#x2013; clinical and genetic factors at the edges of the survival spectrum. Neurobiol. Aging 119, 117&#x2013;126 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35933239</ArticleId><ArticleId IdType="doi">10.1016/j.neurobiolaging.2022.07.005</ArticleId></ArticleIdList></Reference><Reference><Citation>Dorst, J. et al. Patients with elevated triglyceride and cholesterol serum levels have a prolonged survival in amyotrophic lateral sclerosis. J. Neurol. 258, 613&#x2013;617 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21128082</ArticleId><ArticleId IdType="doi">10.1007/s00415-010-5805-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Dupuis, L. et al. Dyslipidemia is a protective factor in amyotrophic lateral sclerosis. Neurology 70, 1004&#x2013;1009 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18199832</ArticleId><ArticleId IdType="doi">10.1212/01.wnl.0000285080.70324.27</ArticleId></ArticleIdList></Reference><Reference><Citation>Chio, A. et al. Lower serum lipid levels are related to respiratory impairment in patients with ALS. Neurology 73, 1681&#x2013;1685 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19917991</ArticleId><ArticleId IdType="doi">10.1212/WNL.0b013e3181c1df1e</ArticleId></ArticleIdList></Reference><Reference><Citation>Tandan, R. et al. Body composition in amyotrophic lateral sclerosis subjects and its effect on disease progression and survival. Am. J. Clin. Nutr. 115, 1378&#x2013;1392 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35108352</ArticleId><ArticleId IdType="pmc">9071423</ArticleId><ArticleId IdType="doi">10.1093/ajcn/nqac016</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee, I. et al. Fat mass loss correlates with faster disease progression in amyotrophic lateral sclerosis patients: exploring the utility of dual-energy x-ray absorptiometry in a prospective study. PLoS ONE 16, e0251087 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33956876</ArticleId><ArticleId IdType="pmc">8101939</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0251087</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindauer, E. et al. Adipose tissue distribution predicts survival in amyotrophic lateral sclerosis. PLoS ONE 8, e67783 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23826340</ArticleId><ArticleId IdType="pmc">3694869</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0067783</ArticleId></ArticleIdList></Reference><Reference><Citation>Paganoni, S., Deng, J., Jaffa, M., Cudkowicz, M. E. &amp; Wills, A. M. Body mass index, not dyslipidemia, is an independent predictor of survival in amyotrophic lateral sclerosis. Muscle Nerve 44, 20&#x2013;24 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21607987</ArticleId><ArticleId IdType="pmc">4441750</ArticleId><ArticleId IdType="doi">10.1002/mus.22114</ArticleId></ArticleIdList></Reference><Reference><Citation>Ngo, S. T. et al. Loss of appetite is associated with a loss of weight and fat mass in patients with amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Frontotemporal Degener. 20, 497&#x2013;505 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31144522</ArticleId><ArticleId IdType="doi">10.1080/21678421.2019.1621346</ArticleId></ArticleIdList></Reference><Reference><Citation>Moglia, C. et al. Early weight loss in amyotrophic lateral sclerosis: outcome relevance and clinical correlates in a population-based cohort. J. Neurol. Neurosurg. Psychiatry 90, 666&#x2013;673 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30630957</ArticleId><ArticleId IdType="doi">10.1136/jnnp-2018-319611</ArticleId></ArticleIdList></Reference><Reference><Citation>Mezoian, T. et al. Loss of appetite in amyotrophic lateral sclerosis is associated with weight loss and decreased calorie consumption independent of dysphagia. Muscle Nerve 61, 230&#x2013;234 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">31650547</ArticleId><ArticleId IdType="doi">10.1002/mus.26749</ArticleId></ArticleIdList></Reference><Reference><Citation>Mariosa, D. et al. Body mass index and amyotrophic lateral sclerosis: a study of US military veterans. Am. J. Epidemiol. 185, 362&#x2013;371 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28158443</ArticleId><ArticleId IdType="pmc">5860019</ArticleId><ArticleId IdType="doi">10.1093/aje/kww140</ArticleId></ArticleIdList></Reference><Reference><Citation>Westeneng, H. J. et al. Associations between lifestyle and amyotrophic lateral sclerosis stratified by C9orf72 genotype: a longitudinal, population-based, case-control study. Lancet Neurol. 20, 373&#x2013;384 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33894192</ArticleId><ArticleId IdType="doi">10.1016/S1474-4422(21)00042-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Peter, R. S. et al. Life course body mass index and risk and prognosis of amyotrophic lateral sclerosis: results from the ALS registry Swabia. Eur. J. Epidemiol. 32, 901&#x2013;908 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28975435</ArticleId><ArticleId IdType="doi">10.1007/s10654-017-0318-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagel, G. et al. Adipokines, C-reactive protein and amyotrophic lateral sclerosis &#x2013; results from a population- based ALS registry in Germany. Sci. Rep. 7, 4374 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28663573</ArticleId><ArticleId IdType="pmc">5491500</ArticleId><ArticleId IdType="doi">10.1038/s41598-017-04706-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagel, G. et al. Association of insulin-like growth factor 1 concentrations with risk for and prognosis of amyotrophic lateral sclerosis &#x2013; results from the ALS registry Swabia. Sci. Rep. 10, 736 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">31959864</ArticleId><ArticleId IdType="pmc">6971302</ArticleId><ArticleId IdType="doi">10.1038/s41598-020-57744-x</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenbohm, A. et al. Association of serum retinol-binding protein 4 concentration with risk for and prognosis of amyotrophic lateral sclerosis. JAMA Neurol. 75, 600&#x2013;607 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29482216</ArticleId><ArticleId IdType="pmc">5885207</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2017.5129</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallo, V. et al. Prediagnostic body fat and risk of death from amyotrophic lateral sclerosis: the EPIC cohort. Neurology 80, 829&#x2013;838 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23390184</ArticleId><ArticleId IdType="pmc">3598455</ArticleId><ArticleId IdType="doi">10.1212/WNL.0b013e3182840689</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakken, O., Meyer, H. E., Stigum, H. &amp; Holmoy, T. High BMI is associated with low ALS risk: a population-based study. Neurology 93, e424&#x2013;e432 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31243073</ArticleId><ArticleId IdType="doi">10.1212/WNL.0000000000007861</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Reilly, E. J. et al. Prediagnostic body size and risk of amyotrophic lateral sclerosis death in 10 studies. Amyotroph. Lateral Scler. Frontotemporal Degener. 19, 396&#x2013;406 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29658324</ArticleId><ArticleId IdType="pmc">6423444</ArticleId><ArticleId IdType="doi">10.1080/21678421.2018.1452944</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson, P., Lonnstedt, I., Nygren, I. &amp; Askmark, H. Physical fitness, but not muscle strength, is a risk factor for death in amyotrophic lateral sclerosis at an early age. J. Neurol. Neurosurg. Psychiatry 83, 390&#x2013;394 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">20852312</ArticleId><ArticleId IdType="doi">10.1136/jnnp.2010.218982</ArticleId></ArticleIdList></Reference><Reference><Citation>Bjornevik, K. et al. Pre-diagnostic plasma lipid levels and the risk of amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Frontotemporal Degener. 22, 133&#x2013;143 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">32985910</ArticleId><ArticleId IdType="doi">10.1080/21678421.2020.1822411</ArticleId></ArticleIdList></Reference><Reference><Citation>Steyn, F. J. et al. Altered skeletal muscle glucose&#x2013;fatty acid flux in amyotrophic lateral sclerosis. Brain Commun. 2, fcaa154 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">33241210</ArticleId><ArticleId IdType="pmc">7677608</ArticleId><ArticleId IdType="doi">10.1093/braincomms/fcaa154</ArticleId></ArticleIdList></Reference><Reference><Citation>Dupuis, L., Oudart, H., Rene, F., Gonzalez de Aguilar, J. L. &amp; Loeffler, J. P. Evidence for defective energy homeostasis in amyotrophic lateral sclerosis: benefit of a high-energy diet in a transgenic mouse model. Proc. Natl Acad. Sci. USA 101, 11159&#x2013;11164 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15263088</ArticleId><ArticleId IdType="pmc">503756</ArticleId><ArticleId IdType="doi">10.1073/pnas.0402026101</ArticleId></ArticleIdList></Reference><Reference><Citation>Boillee, S. et al. Onset and progression in inherited ALS determined by motor neurons and microglia. Science 312, 1389&#x2013;1392 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16741123</ArticleId><ArticleId IdType="doi">10.1126/science.1123511</ArticleId></ArticleIdList></Reference><Reference><Citation>Coughlan, K. S., Halang, L., Woods, I. &amp; Prehn, J. H. A high-fat jelly diet restores bioenergetic balance and extends lifespan in the presence of motor dysfunction and lumbar spinal cord motor neuron loss in TDP-43<sup>A315T</sup> mutant C57BL6/J mice. Dis. Model. Mech. 9, 1029&#x2013;1037 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27491077</ArticleId><ArticleId IdType="pmc">5047697</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludolph, A. C., Hugon, J., Dwivedi, M. P., Schaumburg, H. H. &amp; Spencer, P. S. Studies on the aetiology and pathogenesis of motor neuron diseases. 1. Lathyrism: clinical findings in established cases. Brain 110, 149&#x2013;165 (1987).</Citation><ArticleIdList><ArticleId IdType="pubmed">3801847</ArticleId><ArticleId IdType="doi">10.1093/brain/110.1.149</ArticleId></ArticleIdList></Reference><Reference><Citation>Hugon, J., Ludolph, A., Roy, D. N., Schaumburg, H. H. &amp; Spencer, P. S. Studies on the etiology and pathogenesis of motor neuron diseases. II. Clinical and electrophysiologic features of pyramidal dysfunction in macaques fed Lathyrus sativus and IDPN. Neurology 38, 435&#x2013;442 (1988).</Citation><ArticleIdList><ArticleId IdType="pubmed">3347349</ArticleId><ArticleId IdType="doi">10.1212/WNL.38.3.435</ArticleId></ArticleIdList></Reference><Reference><Citation>Spencer, P. S. et al. Lathyrism: evidence for role of the neuroexcitatory aminoacid BOAA. Lancet 2, 1066&#x2013;1067 (1986).</Citation><ArticleIdList><ArticleId IdType="pubmed">2877226</ArticleId><ArticleId IdType="doi">10.1016/S0140-6736(86)90468-X</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, L., Tang, L., Huang, T. &amp; Fan, D. Life course adiposity and amyotrophic lateral sclerosis: a Mendelian randomization study. Ann. Neurol. 87, 434&#x2013;441 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">31916305</ArticleId><ArticleId IdType="doi">10.1002/ana.25671</ArticleId></ArticleIdList></Reference><Reference><Citation>van Rheenen, W. et al. Author Correction: Common and rare variant association analyses in amyotrophic lateral sclerosis identify 15 risk loci with distinct genetic architectures and neuron-specific biology. Nat. Genet. 54, 361 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35102318</ArticleId><ArticleId IdType="pmc">8920884</ArticleId><ArticleId IdType="doi">10.1038/s41588-022-01020-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Bandres-Ciga, S. et al. Shared polygenic risk and causal inferences in amyotrophic lateral sclerosis. Ann. Neurol. 85, 470&#x2013;481 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30723964</ArticleId><ArticleId IdType="pmc">6450729</ArticleId><ArticleId IdType="doi">10.1002/ana.25431</ArticleId></ArticleIdList></Reference><Reference><Citation>Esteban-Garcia, N. et al. Body complexion and circulating lipids in the risk of TDP-43 related disorders. Front. Aging Neurosci. 14, 838141 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35401153</ArticleId><ArticleId IdType="pmc">8990802</ArticleId><ArticleId IdType="doi">10.3389/fnagi.2022.838141</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng, P., Wang, T., Zheng, J. &amp; Zhou, X. Causal association of type 2 diabetes with amyotrophic lateral sclerosis: new evidence from Mendelian randomization using GWAS summary statistics. BMC Med. 17, 225 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31796040</ArticleId><ArticleId IdType="pmc">6892209</ArticleId><ArticleId IdType="doi">10.1186/s12916-019-1448-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen, H. et al. Type 2 diabetes mellitus and amyotrophic lateral sclerosis: genetic overlap, causality, and mediation. J. Clin. Endocrinol. Metab. 106, e4497&#x2013;e4508 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34171091</ArticleId><ArticleId IdType="doi">10.1210/clinem/dgab465</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, L., Tang, L., Huang, T. &amp; Fan, D. Association between type 2 diabetes and amyotrophic lateral sclerosis. Sci. Rep. 12, 2544 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35169211</ArticleId><ArticleId IdType="pmc">8847454</ArticleId><ArticleId IdType="doi">10.1038/s41598-022-06463-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Hop, P. J. et al. Genome-wide study of DNA methylation shows alterations in metabolic, inflammatory, and cholesterol pathways in ALS. Sci. Transl. Med. 14, eabj0264 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35196023</ArticleId><ArticleId IdType="pmc">10040186</ArticleId><ArticleId IdType="doi">10.1126/scitranslmed.abj0264</ArticleId></ArticleIdList></Reference><Reference><Citation>Ngo, S. T., Mi, J. D., Henderson, R. D., McCombe, P. A. &amp; Steyn, F. J. Exploring targets and therapies for amyotrophic lateral sclerosis: current insights into dietary interventions. Degener. Neurol. Neuro 7, 95&#x2013;108 (2017).</Citation></Reference><Reference><Citation>Booth, F. W. Effect of limb immobilization on skeletal muscle. J. Appl. Physiol. Respir. Environ. Exerc. Physiol. 52, 1113&#x2013;1118 (1982).</Citation><ArticleIdList><ArticleId IdType="pubmed">7047468</ArticleId></ArticleIdList></Reference><Reference><Citation>Burgos, R. et al. ESPEN guideline clinical nutrition in neurology. Clin. Nutr. 37, 354&#x2013;396 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29274834</ArticleId><ArticleId IdType="doi">10.1016/j.clnu.2017.09.003</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#x3cc;pez-G&#x3cc;mez, J. J. et al. Malnutrition at diagnosis in amyotrophic lateral sclerosis (als) and its influence on survival: using GLIM criteria. Clin. Nutr. 40, 237&#x2013;244 (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clnu.2020.05.014</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorges, M. et al. Hypothalamic atrophy is related to body mass index and age at onset in amyotrophic lateral sclerosis. J. Neurol. Neurosurg. Psychiatry 88, 1033&#x2013;1041 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28596251</ArticleId><ArticleId IdType="doi">10.1136/jnnp-2017-315795</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang, J. et al. Lower hypothalamic volume with lower body mass index is associated with shorter survival in patients with amyotrophic lateral sclerosis. Eur. J. Neurol. 30, 57&#x2013;68 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">36214080</ArticleId><ArticleId IdType="doi">10.1111/ene.15589</ArticleId></ArticleIdList></Reference><Reference><Citation>Gabery, S. et al. Loss of the metabolism and sleep regulating neuronal populations expressing orexin and oxytocin in the hypothalamus in amyotrophic lateral sclerosis. Neuropathol. Appl. Neurobiol. 47, 979&#x2013;989 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33755993</ArticleId><ArticleId IdType="doi">10.1111/nan.12709</ArticleId></ArticleIdList></Reference><Reference><Citation>Desport, J. C. et al. Factors correlated with hypermetabolism in patients with amyotrophic lateral sclerosis. Am. J. Clin. Nutr. 74, 328&#x2013;334 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11522556</ArticleId><ArticleId IdType="doi">10.1093/ajcn/74.3.328</ArticleId></ArticleIdList></Reference><Reference><Citation>Desport, J. C., Torny, F., Lacoste, M., Preux, P. M. &amp; Couratier, P. Hypermetabolism in ALS: correlations with clinical and paraclinical parameters. Neurodegener. Dis. 2, 202&#x2013;207 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">16909026</ArticleId><ArticleId IdType="doi">10.1159/000089626</ArticleId></ArticleIdList></Reference><Reference><Citation>Bouteloup, C. et al. Hypermetabolism in ALS patients: an early and persistent phenomenon. J. Neurol. 256, 1236&#x2013;1242 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19306035</ArticleId><ArticleId IdType="doi">10.1007/s00415-009-5100-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Funalot, B., Desport, J. C., Sturtz, F., Camu, W. &amp; Couratier, P. High metabolic level in patients with familial amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. 10, 113&#x2013;117 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">18792852</ArticleId><ArticleId IdType="doi">10.1080/17482960802295192</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaisman, N. et al. Do patients with amyotrophic lateral sclerosis (ALS) have increased energy needs. J. Neurol. Sci. 279, 26&#x2013;29 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19185883</ArticleId><ArticleId IdType="doi">10.1016/j.jns.2008.12.027</ArticleId></ArticleIdList></Reference><Reference><Citation>J&#xe9;sus, P. et al. Hypermetabolism is a deleterious prognostic factor in patients with amyotrophic lateral sclerosis. Eur. J. Neurol. 25, 97&#x2013;104 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">28940704</ArticleId><ArticleId IdType="doi">10.1111/ene.13468</ArticleId></ArticleIdList></Reference><Reference><Citation>Steyn, F. J. et al. Hypermetabolism in ALS is associated with greater functional decline and shorter survival. J. Neurol. Neurosurg. Psychiatry 89, 1016&#x2013;1023 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29706605</ArticleId><ArticleId IdType="doi">10.1136/jnnp-2017-317887</ArticleId></ArticleIdList></Reference><Reference><Citation>J&#xe9;sus, P. et al. Increased resting energy expenditure compared with predictive theoretical equations in amyotrophic lateral sclerosis. Nutrition 77, 110805 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32371347</ArticleId><ArticleId IdType="doi">10.1016/j.nut.2020.110805</ArticleId></ArticleIdList></Reference><Reference><Citation>Ngo, S. T. et al. Progression and survival of patients with motor neuron disease relative to their fecal microbiota. Amyotroph. Lateral Scler. Frontotemporal Degener. 21, 549&#x2013;562 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32643435</ArticleId><ArticleId IdType="doi">10.1080/21678421.2020.1772825</ArticleId></ArticleIdList></Reference><Reference><Citation>Fayemendy, P. et al. Hypermetabolism is a reality in amyotrophic lateral sclerosis compared to healthy subjects. J. Neurol. Sci. 420, 117257 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33290920</ArticleId><ArticleId IdType="doi">10.1016/j.jns.2020.117257</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakamura, R. et al. Prognostic prediction by hypermetabolism varies depending on the nutritional status in early amyotrophic lateral sclerosis. Sci. Rep. 11, 17943 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34504168</ArticleId><ArticleId IdType="pmc">8429558</ArticleId><ArticleId IdType="doi">10.1038/s41598-021-97196-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Cattaneo, M. et al. The hypometabolic state: a good predictor of a better prognosis in amyotrophic lateral sclerosis. J. Neurol. Neurosurg. Psychiatry 93, 41&#x2013;47 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">34353859</ArticleId><ArticleId IdType="doi">10.1136/jnnp-2021-326184</ArticleId></ArticleIdList></Reference><Reference><Citation>He, J. et al. Hypermetabolism associated with worse prognosis of amyotrophic lateral sclerosis. J. Neurol. 269, 1447&#x2013;1455 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">34274994</ArticleId><ArticleId IdType="doi">10.1007/s00415-021-10716-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakamura, R. et al. Investigation of the prognostic predictive value of serum lipid profiles in amyotrophic lateral sclerosis: roles of sex and hypermetabolism. Sci. Rep. 12, 1826 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35115598</ArticleId><ArticleId IdType="pmc">8814149</ArticleId><ArticleId IdType="doi">10.1038/s41598-022-05714-w</ArticleId></ArticleIdList></Reference><Reference><Citation>Zurlo, F., Larson, K., Bogardus, C. &amp; Ravussin, E. Skeletal muscle metabolism is a major determinant of resting energy expenditure. J. Clin. Invest. 86, 1423&#x2013;1427 (1990).</Citation><ArticleIdList><ArticleId IdType="pubmed">2243122</ArticleId><ArticleId IdType="pmc">296885</ArticleId><ArticleId IdType="doi">10.1172/JCI114857</ArticleId></ArticleIdList></Reference><Reference><Citation>Georges, M., Morelot-Panzini, C., Similowski, T. &amp; Gonzalez-Bermejo, J. Noninvasive ventilation reduces energy expenditure in amyotrophic lateral sclerosis. BMC Pulm. Med. 14, 17 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24507664</ArticleId><ArticleId IdType="pmc">3922008</ArticleId><ArticleId IdType="doi">10.1186/1471-2466-14-17</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferri, A. &amp; Coccurello, R. What is &#x201c;hyper&#x201d; in the ALS hypermetabolism? Mediators Inflamm. 2017, 7821672 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">29081604</ArticleId><ArticleId IdType="pmc">5610793</ArticleId><ArticleId IdType="doi">10.1155/2017/7821672</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith, E. F., Shaw, P. J. &amp; De Vos, K. J. The role of mitochondria in amyotrophic lateral sclerosis. Neurosci. Lett. 710, 132933 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">28669745</ArticleId><ArticleId IdType="doi">10.1016/j.neulet.2017.06.052</ArticleId></ArticleIdList></Reference><Reference><Citation>Dorst, J. et al. Metabolic alterations precede neurofilament changes in presymptomatic ALS gene carriers. EBioMedicine 90, 104521 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">36917918</ArticleId><ArticleId IdType="pmc">10024076</ArticleId><ArticleId IdType="doi">10.1016/j.ebiom.2023.104521</ArticleId></ArticleIdList></Reference><Reference><Citation>Genin, E. C. et al. CHCHD10 mutations promote loss of mitochondrial cristae junctions with impaired mitochondrial genome maintenance and inhibition of apoptosis. EMBO Mol. Med. 8, 58&#x2013;72 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26666268</ArticleId><ArticleId IdType="doi">10.15252/emmm.201505496</ArticleId></ArticleIdList></Reference><Reference><Citation>Genin, E. C. et al. Mitochondrial defect in muscle precedes neuromuscular junction degeneration and motor neuron death in CHCHD10<sup>S59L/+</sup> mouse. Acta Neuropathol. 138, 123&#x2013;145 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30874923</ArticleId><ArticleId IdType="doi">10.1007/s00401-019-01988-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Genin, E. C. et al. Loss of MICOS complex integrity and mitochondrial damage, but not TDP-43 mitochondrial localisation, are likely associated with severity of CHCHD10-related diseases. Neurobiol. Dis. 119, 159&#x2013;171 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30092269</ArticleId><ArticleId IdType="pmc">7015038</ArticleId><ArticleId IdType="doi">10.1016/j.nbd.2018.07.027</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, T. et al. C9orf72 regulates energy homeostasis by stabilizing mitochondrial complex I assembly. Cell Metab. 33, 531&#x2013;546.e9 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33545050</ArticleId><ArticleId IdType="pmc">8579819</ArticleId><ArticleId IdType="doi">10.1016/j.cmet.2021.01.005</ArticleId></ArticleIdList></Reference><Reference><Citation>Onesto, E. et al. Gene-specific mitochondria dysfunctions in human TARDBP and C9ORF72 fibroblasts. Acta Neuropathol. Commun. 4, 47 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27151080</ArticleId><ArticleId IdType="pmc">4858818</ArticleId><ArticleId IdType="doi">10.1186/s40478-016-0316-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Gunther, R. et al. Alteration of mitochondrial integrity as upstream event in the pathophysiology of SOD1-ALS. Cells https://doi.org/10.3390/cells11071246 (2022).</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells11071246</ArticleId><ArticleId IdType="pubmed">35626753</ArticleId><ArticleId IdType="pmc">9139186</ArticleId></ArticleIdList></Reference><Reference><Citation>Devoy, A. et al. Humanized mutant FUS drives progressive motor neuron degeneration without aggregation in &#x2018;FUSDelta14&#x2019; knockin mice. Brain 140, 2797&#x2013;2805 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">29053787</ArticleId><ArticleId IdType="pmc">5841203</ArticleId><ArticleId IdType="doi">10.1093/brain/awx248</ArticleId></ArticleIdList></Reference><Reference><Citation>Shan, X., Chiang, P. M., Price, D. L. &amp; Wong, P. C. Altered distributions of Gemini of coiled bodies and mitochondria in motor neurons of TDP-43 transgenic mice. Proc. Natl Acad. Sci. USA 107, 16325&#x2013;16330 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20736350</ArticleId><ArticleId IdType="pmc">2941282</ArticleId><ArticleId IdType="doi">10.1073/pnas.1003459107</ArticleId></ArticleIdList></Reference><Reference><Citation>Izumikawa, K. et al. TDP-43 stabilises the processing intermediates of mitochondrial transcripts. Sci. Rep. 7, 7709 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28794432</ArticleId><ArticleId IdType="pmc">5550480</ArticleId><ArticleId IdType="doi">10.1038/s41598-017-06953-y</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, W. et al. The inhibition of TDP-43 mitochondrial localization blocks its neuronal toxicity. Nat. Med. 22, 869&#x2013;878 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27348499</ArticleId><ArticleId IdType="pmc">4974139</ArticleId><ArticleId IdType="doi">10.1038/nm.4130</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, P. et al. TDP-43 induces mitochondrial damage and activates the mitochondrial unfolded protein response. PLoS Genet. 15, e1007947 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31100073</ArticleId><ArticleId IdType="pmc">6524796</ArticleId><ArticleId IdType="doi">10.1371/journal.pgen.1007947</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuo, X. et al. TDP-43 aggregation induced by oxidative stress causes global mitochondrial imbalance in ALS. Nat. Struct. Mol. Biol. 28, 132&#x2013;142 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33398173</ArticleId><ArticleId IdType="doi">10.1038/s41594-020-00537-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawamata, H. et al. Mutant TDP-43 does not impair mitochondrial bioenergetics in vitro and in vivo. Mol. Neurodegener. 12, 37 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28482850</ArticleId><ArticleId IdType="pmc">5422931</ArticleId><ArticleId IdType="doi">10.1186/s13024-017-0180-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Dafinca, R. et al. Impairment of mitochondrial calcium buffering links mutations in C9ORF72 and TARDBP in iPS-derived motor neurons from patients with ALS/FTD. Stem Cell Rep. 14, 892&#x2013;908 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stemcr.2020.03.023</ArticleId></ArticleIdList></Reference><Reference><Citation>Fazal, R. et al. HDAC6 inhibition restores TDP-43 pathology and axonal transport defects in human motor neurons with TARDBP mutations. EMBO J. 40, e106177 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33694180</ArticleId><ArticleId IdType="pmc">8013789</ArticleId><ArticleId IdType="doi">10.15252/embj.2020106177</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakaya, T. &amp; Maragkakis, M. Amyotrophic lateral sclerosis associated FUS mutation shortens mitochondria and induces neurotoxicity. Sci. Rep. 8, 15575 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30349096</ArticleId><ArticleId IdType="pmc">6197261</ArticleId><ArticleId IdType="doi">10.1038/s41598-018-33964-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai, Y. L. et al. ALS/FTD-associated protein FUS induces mitochondrial dysfunction by preferentially sequestering respiratory chain complex mRNAs. Genes Dev. 34, 785&#x2013;805 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32381627</ArticleId><ArticleId IdType="pmc">7263147</ArticleId><ArticleId IdType="doi">10.1101/gad.335836.119</ArticleId></ArticleIdList></Reference><Reference><Citation>Salam, S. et al. Identification of a novel interaction of FUS and syntaphilin may explain synaptic and mitochondrial abnormalities caused by ALS mutations. Sci. Rep. 11, 13613 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34193962</ArticleId><ArticleId IdType="pmc">8245466</ArticleId><ArticleId IdType="doi">10.1038/s41598-021-93189-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Stoica, R. et al. ALS/FTD-associated FUS activates GSK-3&#x3b2; to disrupt the VAPB-PTPIP51 interaction and ER-mitochondria associations. EMBO Rep. 17, 1326&#x2013;1342 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27418313</ArticleId><ArticleId IdType="pmc">5007559</ArticleId><ArticleId IdType="doi">10.15252/embr.201541726</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng, J. et al. FUS interacts with HSP60 to promote mitochondrial damage. PLoS Genet. 11, e1005357 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26335776</ArticleId><ArticleId IdType="pmc">4559378</ArticleId><ArticleId IdType="doi">10.1371/journal.pgen.1005357</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng, J. et al. FUS interacts with ATP synthase beta subunit and induces mitochondrial unfolded protein response in cellular and animal models. Proc. Natl Acad. Sci. USA 115, E9678&#x2013;E9686 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30249657</ArticleId><ArticleId IdType="pmc">6187197</ArticleId><ArticleId IdType="doi">10.1073/pnas.1806655115</ArticleId></ArticleIdList></Reference><Reference><Citation>Briese, M. et al. Loss of Tdp-43 disrupts the axonal transcriptome of motoneurons accompanied by impaired axonal translation and mitochondria function. Acta Neuropathol. Commun. 8, 116 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32709255</ArticleId><ArticleId IdType="pmc">7379803</ArticleId><ArticleId IdType="doi">10.1186/s40478-020-00987-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Altman, T. et al. Axonal TDP-43 condensates drive neuromuscular junction disruption through inhibition of local synthesis of nuclear encoded mitochondrial proteins. Nat. Commun. 12, 6914 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34824257</ArticleId><ArticleId IdType="pmc">8617040</ArticleId><ArticleId IdType="doi">10.1038/s41467-021-27221-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Allen, S. P. et al. C9orf72 expansion within astrocytes reduces metabolic flexibility in amyotrophic lateral sclerosis. Brain 142, 3771&#x2013;3790 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31647549</ArticleId><ArticleId IdType="pmc">6906594</ArticleId><ArticleId IdType="doi">10.1093/brain/awz302</ArticleId></ArticleIdList></Reference><Reference><Citation>Allen, S. P. et al. Astrocyte adenosine deaminase loss increases motor neuron toxicity in amyotrophic lateral sclerosis. Brain 142, 586&#x2013;605 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30698736</ArticleId><ArticleId IdType="pmc">6391613</ArticleId><ArticleId IdType="doi">10.1093/brain/awy353</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu, M. et al. Widespread mislocalization of FUS is associated with mitochondrial abnormalities in skeletal muscle in amyotrophic lateral sclerosis with FUS mutations. J. Neuropathol. Exp. Neurol. 81, 172&#x2013;181 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35139534</ArticleId><ArticleId IdType="doi">10.1093/jnen/nlac004</ArticleId></ArticleIdList></Reference><Reference><Citation>Badu-Mensah, A., Guo, X., McAleer, C. W., Rumsey, J. W. &amp; Hickman, J. J. Functional skeletal muscle model derived from SOD1-mutant ALS patient iPSCs recapitulates hallmarks of disease progression. Sci. Rep. 10, 14302 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32868812</ArticleId><ArticleId IdType="pmc">7459299</ArticleId><ArticleId IdType="doi">10.1038/s41598-020-70510-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Marini, C. et al. Mechanisms underlying the predictive power of high skeletal muscle uptake of FDG in amyotrophic lateral sclerosis. EJNMMI Res. 10, 76 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32638178</ArticleId><ArticleId IdType="pmc">7340686</ArticleId><ArticleId IdType="doi">10.1186/s13550-020-00666-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobrowolny, G. et al. Skeletal muscle is a primary target of SOD1<sup>G93A</sup>-mediated toxicity. Cell Metab. 8, 425&#x2013;436 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">19046573</ArticleId><ArticleId IdType="doi">10.1016/j.cmet.2008.09.002</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobrowolny, G. et al. Metabolic changes associated with muscle expression of SOD1<sup>G93A</sup>. Front. Physiol. 9, 831 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30042688</ArticleId><ArticleId IdType="pmc">6048270</ArticleId><ArticleId IdType="doi">10.3389/fphys.2018.00831</ArticleId></ArticleIdList></Reference><Reference><Citation>Scaricamazza, S. et al. Skeletal-muscle metabolic reprogramming in ALS-SOD1<sup>G93A</sup> mice predates disease onset and is a promising therapeutic target. iScience 23, 101087 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32371370</ArticleId><ArticleId IdType="pmc">7200935</ArticleId><ArticleId IdType="doi">10.1016/j.isci.2020.101087</ArticleId></ArticleIdList></Reference><Reference><Citation>Palamiuc, L. et al. A metabolic switch toward lipid use in glycolytic muscle is an early pathologic event in a mouse model of amyotrophic lateral sclerosis. EMBO Mol. Med. 7, 526&#x2013;546 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25820275</ArticleId><ArticleId IdType="pmc">4492815</ArticleId><ArticleId IdType="doi">10.15252/emmm.201404433</ArticleId></ArticleIdList></Reference><Reference><Citation>Wills, A. M. et al. Hypercaloric enteral nutrition in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet 383, 2065&#x2013;2072 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24582471</ArticleId><ArticleId IdType="pmc">4176708</ArticleId><ArticleId IdType="doi">10.1016/S0140-6736(14)60222-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Dorst, J. et al. Percutaneous endoscopic gastrostomy in amyotrophic lateral sclerosis: a prospective observational study. J. Neurol. 262, 849&#x2013;858 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25618254</ArticleId><ArticleId IdType="doi">10.1007/s00415-015-7646-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludolph, A. C. et al. Effect of high-caloric nutrition on survival in amyotrophic lateral sclerosis. Ann. Neurol. 87, 206&#x2013;216 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">31849093</ArticleId><ArticleId IdType="doi">10.1002/ana.25661</ArticleId></ArticleIdList></Reference><Reference><Citation>Dorst, J. et al. Effect of high-caloric nutrition on serum neurofilament light chain levels in amyotrophic lateral sclerosis. J. Neurol. Neurosurg. Psychiatry 91, 1007&#x2013;1009 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32788256</ArticleId><ArticleId IdType="doi">10.1136/jnnp-2020-323372</ArticleId></ArticleIdList></Reference><Reference><Citation>Dorst, J. et al. Fat-rich versus carbohydrate-rich nutrition in ALS: a randomised controlled study. J. Neurol. Neurosurg. Psychiatry 93, 298&#x2013;302 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35022317</ArticleId><ArticleId IdType="doi">10.1136/jnnp-2021-328331</ArticleId></ArticleIdList></Reference><Reference><Citation>Coates, E. et al. Patient, carer and healthcare professional perspectives on increasing calorie intake in amyotrophic lateral sclerosis. Chronic Illn. 19, 368&#x2013;382 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">34935521</ArticleId><ArticleId IdType="doi">10.1177/17423953211069090</ArticleId></ArticleIdList></Reference><Reference><Citation>Zarotti, N. et al. Health care professionals&#x2019; views on psychological factors affecting nutritional behaviour in people with motor neuron disease: a thematic analysis. Br. J. Health Psychol. 24, 953&#x2013;969 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31449739</ArticleId><ArticleId IdType="doi">10.1111/bjhp.12388</ArticleId></ArticleIdList></Reference><Reference><Citation>Biomed Central. ISCRTN registry https://www.isrctn.com/ISRCTN30588041 (2020).</Citation></Reference><Reference><Citation>Randle, P. J., Garland, P. B., Hales, C. N. &amp; Newsholme, E. A. The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1, 785&#x2013;789 (1963).</Citation><ArticleIdList><ArticleId IdType="pubmed">13990765</ArticleId><ArticleId IdType="doi">10.1016/S0140-6736(63)91500-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Ray, P. D., Huang, B. W. &amp; Tsuji, Y. Reactive oxygen species (ROS) homeostasis and redox regulation in cellular signaling. Cell Signal. 24, 981&#x2013;990 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22286106</ArticleId><ArticleId IdType="pmc">3454471</ArticleId><ArticleId IdType="doi">10.1016/j.cellsig.2012.01.008</ArticleId></ArticleIdList></Reference><Reference><Citation>Browne, S. E. et al. Bioenergetic abnormalities in discrete cerebral motor pathways presage spinal cord pathology in the G93A SOD1 mouse model of ALS. Neurobiol. Dis. 22, 599&#x2013;610 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16616851</ArticleId><ArticleId IdType="doi">10.1016/j.nbd.2006.01.001</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo, Z., Kindy, M. S., Kruman, I. &amp; Mattson, M. P. ALS-linked Cu/Zn-SOD mutation impairs cerebral synaptic glucose and glutamate transport and exacerbates ischemic brain injury. J. Cereb. Blood Flow. Metab. 20, 463&#x2013;468 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">10724110</ArticleId><ArticleId IdType="doi">10.1097/00004647-200003000-00004</ArticleId></ArticleIdList></Reference><Reference><Citation>Manzo, E. et al. Glycolysis upregulation is neuroprotective as a compensatory mechanism in ALS. Elife https://doi.org/10.7554/eLife.45114 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.45114</ArticleId><ArticleId IdType="pubmed">31180318</ArticleId><ArticleId IdType="pmc">6557627</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez-Palma, L. et al. Mitochondrial modulation by dichloroacetate reduces toxicity of aberrant glial cells and gliosis in the SOD1G93A rat model of amyotrophic lateral sclerosis. Neurotherapeutics 16, 203&#x2013;215 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30159850</ArticleId><ArticleId IdType="doi">10.1007/s13311-018-0659-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyazaki, K. et al. Early and progressive impairment of spinal blood flow-glucose metabolism coupling in motor neuron degeneration of ALS model mice. J. Cereb. Blood Flow. Metab. 32, 456&#x2013;467 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22068226</ArticleId><ArticleId IdType="doi">10.1038/jcbfm.2011.155</ArticleId></ArticleIdList></Reference><Reference><Citation>Weerasekera, A. et al. Non-invasive characterization of amyotrophic lateral sclerosis in a hTDP-43<sup>A315T</sup> mouse model: a PET-MR study. Neuroimage Clin. 27, 102327 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32653817</ArticleId><ArticleId IdType="pmc">7352080</ArticleId><ArticleId IdType="doi">10.1016/j.nicl.2020.102327</ArticleId></ArticleIdList></Reference><Reference><Citation>Desseille, C. et al. Specific physical exercise improves energetic metabolism in the skeletal muscle of amyotrophic-lateral-sclerosis mice. Front. Mol. Neurosci. 10, 332 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">29104532</ArticleId><ArticleId IdType="pmc">5655117</ArticleId><ArticleId IdType="doi">10.3389/fnmol.2017.00332</ArticleId></ArticleIdList></Reference><Reference><Citation>Smittkamp, S. E. et al. SOD1-G93A mice exhibit muscle-fiber-type-specific decreases in glucose uptake in the absence of whole-body changes in metabolism. Neurodegener. Dis. 13, 29&#x2013;37 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24021858</ArticleId><ArticleId IdType="doi">10.1159/000351606</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferri, A. et al. Familial ALS-superoxide dismutases associate with mitochondria and shift their redox potentials. Proc. Natl Acad. Sci. USA 103, 13860&#x2013;13865 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16945901</ArticleId><ArticleId IdType="pmc">1557633</ArticleId><ArticleId IdType="doi">10.1073/pnas.0605814103</ArticleId></ArticleIdList></Reference><Reference><Citation>Jung, C., Higgins, C. M. &amp; Xu, Z. Mitochondrial electron transport chain complex dysfunction in a transgenic mouse model for amyotrophic lateral sclerosis. J. Neurochem. 83, 535&#x2013;545 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">12390515</ArticleId><ArticleId IdType="doi">10.1046/j.1471-4159.2002.01112.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirkinezos, I. G. et al. Cytochrome c association with the inner mitochondrial membrane is impaired in the CNS of G93A-SOD1 mice. J. Neurosci. 25, 164&#x2013;172 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15634778</ArticleId><ArticleId IdType="pmc">6725219</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.3829-04.2005</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattiazzi, M. et al. Mutated human SOD1 causes dysfunction of oxidative phosphorylation in mitochondria of transgenic mice. J. Biol. Chem. 277, 29626&#x2013;29633 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">12050154</ArticleId><ArticleId IdType="doi">10.1074/jbc.M203065200</ArticleId></ArticleIdList></Reference><Reference><Citation>Scaricamazza, S. et al. Repurposing of trimetazidine for amyotrophic lateral sclerosis: a study in SOD1<sup>G93A</sup> mice. Br. J. Pharmacol. 179, 1732&#x2013;1752 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">34783031</ArticleId><ArticleId IdType="doi">10.1111/bph.15738</ArticleId></ArticleIdList></Reference><Reference><Citation>Allen, S. P. et al. Superoxide dismutase 1 mutation in a cellular model of amyotrophic lateral sclerosis shifts energy generation from oxidative phosphorylation to glycolysis. Neurobiol. Aging 35, 1499&#x2013;1509 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24439480</ArticleId><ArticleId IdType="doi">10.1016/j.neurobiolaging.2013.11.025</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaytow, H. et al. Targeting phosphoglycerate kinase 1 with terazosin improves motor neuron phenotypes in multiple models of amyotrophic lateral sclerosis. EBioMedicine 83, 104202 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35963713</ArticleId><ArticleId IdType="pmc">9482929</ArticleId><ArticleId IdType="doi">10.1016/j.ebiom.2022.104202</ArticleId></ArticleIdList></Reference><Reference><Citation>Bannwarth, S. et al. A mitochondrial origin for frontotemporal dementia and amyotrophic lateral sclerosis through CHCHD10 involvement. Brain 137, 2329&#x2013;2345 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24934289</ArticleId><ArticleId IdType="pmc">4107737</ArticleId><ArticleId IdType="doi">10.1093/brain/awu138</ArticleId></ArticleIdList></Reference><Reference><Citation>Hor, J. H. et al. ALS motor neurons exhibit hallmark metabolic defects that are rescued by SIRT3 activation. Cell Death Differ. 28, 1379&#x2013;1397 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33184465</ArticleId><ArticleId IdType="doi">10.1038/s41418-020-00664-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta, A. R. et al. Mitochondrial bioenergetic deficits in C9orf72 amyotrophic lateral sclerosis motor neurons cause dysfunctional axonal homeostasis. Acta Neuropathol. 141, 257&#x2013;279 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33398403</ArticleId><ArticleId IdType="pmc">7847443</ArticleId><ArticleId IdType="doi">10.1007/s00401-020-02252-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh, T. et al. Neuronal mitochondrial dysfunction in sporadic amyotrophic lateral sclerosis is developmentally regulated. Sci. Rep. 11, 18916 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34556702</ArticleId><ArticleId IdType="pmc">8460779</ArticleId><ArticleId IdType="doi">10.1038/s41598-021-97928-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Crugnola, V. et al. Mitochondrial respiratory chain dysfunction in muscle from patients with amyotrophic lateral sclerosis. Arch. Neurol. 67, 849&#x2013;854 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20625092</ArticleId><ArticleId IdType="doi">10.1001/archneurol.2010.128</ArticleId></ArticleIdList></Reference><Reference><Citation>Dodge, J. C. et al. Metabolic signatures of amyotrophic lateral sclerosis reveal insights into disease pathogenesis. Proc. Natl Acad. Sci. USA 110, 10812&#x2013;10817 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23754387</ArticleId><ArticleId IdType="pmc">3696768</ArticleId><ArticleId IdType="doi">10.1073/pnas.1308421110</ArticleId></ArticleIdList></Reference><Reference><Citation>Echaniz-Laguna, A. et al. Muscular mitochondrial function in amyotrophic lateral sclerosis is progressively altered as the disease develops: a temporal study in man. Exp. Neurol. 198, 25&#x2013;30 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16126198</ArticleId><ArticleId IdType="doi">10.1016/j.expneurol.2005.07.020</ArticleId></ArticleIdList></Reference><Reference><Citation>Echaniz-Laguna, A. et al. Mitochondrial respiratory chain function in skeletal muscle of ALS patients. Ann. Neurol. 52, 623&#x2013;627 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">12402260</ArticleId><ArticleId IdType="doi">10.1002/ana.10357</ArticleId></ArticleIdList></Reference><Reference><Citation>Canosa, A. et al. Brain metabolic changes across King&#x2019;s stages in amyotrophic lateral sclerosis: a <sup>18</sup>F-2-fluoro-2-deoxy-D-glucose-positron emission tomography study. Eur. J. Nucl. Med. Mol. Imaging 48, 1124&#x2013;1133 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33029654</ArticleId><ArticleId IdType="doi">10.1007/s00259-020-05053-w</ArticleId></ArticleIdList></Reference><Reference><Citation>Canosa, A. et al. <sup>18</sup>F-FDG-PET correlates of cognitive impairment in ALS. Neurology 86, 44&#x2013;49 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26590270</ArticleId><ArticleId IdType="doi">10.1212/WNL.0000000000002242</ArticleId></ArticleIdList></Reference><Reference><Citation>Cistaro, A. et al. The metabolic signature of C9ORF72-related ALS: FDG PET comparison with nonmutated patients. Eur. J. Nucl. Med. Mol. Imaging 41, 844&#x2013;852 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24445987</ArticleId><ArticleId IdType="pmc">8957062</ArticleId><ArticleId IdType="doi">10.1007/s00259-013-2667-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Cistaro, A. et al. Brain hypermetabolism in amyotrophic lateral sclerosis: a FDG PET study in ALS of spinal and bulbar onset. Eur. J. Nucl. Med. Mol. Imaging 39, 251&#x2013;259 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22089661</ArticleId><ArticleId IdType="doi">10.1007/s00259-011-1979-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Dalakas, M. C., Hatazawa, J., Brooks, R. A. &amp; Di Chiro, G. Lowered cerebral glucose utilization in amyotrophic lateral sclerosis. Ann. Neurol. 22, 580&#x2013;586 (1987).</Citation><ArticleIdList><ArticleId IdType="pubmed">3501273</ArticleId><ArticleId IdType="doi">10.1002/ana.410220504</ArticleId></ArticleIdList></Reference><Reference><Citation>Hatazawa, J., Brooks, R. A., Dalakas, M. C., Mansi, L. &amp; Di Chiro, G. Cortical motor-sensory hypometabolism in amyotrophic lateral sclerosis: a PET study. J. Comput. Assist. Tomogr. 12, 630&#x2013;636 (1988).</Citation><ArticleIdList><ArticleId IdType="pubmed">3260610</ArticleId><ArticleId IdType="doi">10.1097/00004728-198807000-00019</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludolph, A. C. et al. Frontal lobe function in amyotrophic lateral sclerosis: a neuropsychologic and positron emission tomography study. Acta Neurol. Scand. 85, 81&#x2013;89 (1992).</Citation><ArticleIdList><ArticleId IdType="pubmed">1574993</ArticleId><ArticleId IdType="doi">10.1111/j.1600-0404.1992.tb04003.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Marini, C. et al. Interplay between spinal cord and cerebral cortex metabolism in amyotrophic lateral sclerosis. Brain 141, 2272&#x2013;2279 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30730551</ArticleId><ArticleId IdType="pmc">6061793</ArticleId><ArticleId IdType="doi">10.1093/brain/awy152</ArticleId></ArticleIdList></Reference><Reference><Citation>Pagani, M. et al. Functional pattern of brain FDG-PET in amyotrophic lateral sclerosis. Neurology 83, 1067&#x2013;1074 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">25122207</ArticleId><ArticleId IdType="doi">10.1212/WNL.0000000000000792</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamashita, T. et al. Flow-metabolism uncoupling in the cervical spinal cord of ALS patients. Neurol. Sci. 38, 659&#x2013;665 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28120243</ArticleId><ArticleId IdType="doi">10.1007/s10072-017-2823-y</ArticleId></ArticleIdList></Reference><Reference><Citation>Andreassen, O. A. et al. Increases in cortical glutamate concentrations in transgenic amyotrophic lateral sclerosis mice are attenuated by creatine supplementation. J. Neurochem. 77, 383&#x2013;390 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11299300</ArticleId><ArticleId IdType="doi">10.1046/j.1471-4159.2001.00188.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Klivenyi, P., Gardian, G., Calingasan, N. Y., Yang, L. &amp; Beal, M. F. Additive neuroprotective effects of creatine and a cyclooxygenase 2 inhibitor against dopamine depletion in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson&#x2019;s disease. J. Mol. Neurosci. 21, 191&#x2013;198 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">14645986</ArticleId><ArticleId IdType="doi">10.1385/JMN:21:3:191</ArticleId></ArticleIdList></Reference><Reference><Citation>Bordet, T. et al. Identification and characterization of cholest-4-en-3-one, oxime (TRO19622), a novel drug candidate for amyotrophic lateral sclerosis. J. Pharmacol. Exp. Ther. 322, 709&#x2013;720 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17496168</ArticleId><ArticleId IdType="doi">10.1124/jpet.107.123000</ArticleId></ArticleIdList></Reference><Reference><Citation>Thams, S. et al. A stem cell-based screening platform identifies compounds that desensitize motor neurons to endoplasmic reticulum stress. Mol. Ther. 27, 87&#x2013;101 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30446391</ArticleId><ArticleId IdType="doi">10.1016/j.ymthe.2018.10.010</ArticleId></ArticleIdList></Reference><Reference><Citation>Schutz, B. et al. The oral antidiabetic pioglitazone protects from neurodegeneration and amyotrophic lateral sclerosis-like symptoms in superoxide dismutase-G93A transgenic mice. J. Neurosci. 25, 7805&#x2013;7812 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">16120782</ArticleId><ArticleId IdType="pmc">6725264</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.2038-05.2005</ArticleId></ArticleIdList></Reference><Reference><Citation>Elia, A. E. et al. Tauroursodeoxycholic acid in the treatment of patients with amyotrophic lateral sclerosis. Eur. J. Neurol. 23, 45&#x2013;52 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">25664595</ArticleId><ArticleId IdType="doi">10.1111/ene.12664</ArticleId></ArticleIdList></Reference><Reference><Citation>Dupuis, L. et al. A randomized, double blind, placebo-controlled trial of pioglitazone in combination with riluzole in amyotrophic lateral sclerosis. PLoS ONE 7, e37885 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22715372</ArticleId><ArticleId IdType="pmc">3371007</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0037885</ArticleId></ArticleIdList></Reference><Reference><Citation>Vercruysse, P. et al. Alterations in the hypothalamic melanocortin pathway in amyotrophic lateral sclerosis. Brain 139, 1106&#x2013;1122 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26984187</ArticleId><ArticleId IdType="doi">10.1093/brain/aww004</ArticleId></ArticleIdList></Reference><Reference><Citation>Luu, L. C. T., Kasarskis, E. J. &amp; Tandan, R. in Amyotrophic Lateral Sclerosis Ch. 32 (eds Mitsumoto, H, Przedborski, S. &amp; Gordon, P. H.) 721&#x2013;735 (Taylor &amp; Francis, 2006).</Citation></Reference><Reference><Citation>Robison, R. et al. Swallowing safety and efficiency impairment profiles in individuals with amyotrophic lateral sclerosis. Dysphagia 37, 644&#x2013;654 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">34037850</ArticleId><ArticleId IdType="doi">10.1007/s00455-021-10315-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Belafsky, P. C. et al. Validity and reliability of the Eating Assessment Tool (EAT-10). Ann. Otol. Rhinol. Laryngol. 117, 919&#x2013;924 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">19140539</ArticleId><ArticleId IdType="doi">10.1177/000348940811701210</ArticleId></ArticleIdList></Reference><Reference><Citation>Cedarbaum, J. M. et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. J. Neurol. Sci. 169, 13&#x2013;21 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10540002</ArticleId><ArticleId IdType="doi">10.1016/S0022-510X(99)00210-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Strand, E. A., Miller, R. M., Yorkston, K. M. &amp; Hillel, A. D. Management of oral-pharyngeal dysphagia symptoms in amyotrophic lateral sclerosis. Dysphagia 11, 129&#x2013;139 (1996).</Citation><ArticleIdList><ArticleId IdType="pubmed">8721072</ArticleId><ArticleId IdType="doi">10.1007/BF00417903</ArticleId></ArticleIdList></Reference><Reference><Citation>Shim, J. S., Oh, K. &amp; Kim, H. C. Dietary assessment methods in epidemiologic studies. Epidemiol. Health 36, e2014009 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">25078382</ArticleId><ArticleId IdType="pmc">4154347</ArticleId><ArticleId IdType="doi">10.4178/epih/e2014009</ArticleId></ArticleIdList></Reference><Reference><Citation>Trabulsi, J. &amp; Schoeller, D. A. Evaluation of dietary assessment instruments against doubly labeled water, a biomarker of habitual energy intake. Am. J. Physiol. Endocrinol. Metab. 281, E891&#x2013;E899 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11595643</ArticleId><ArticleId IdType="doi">10.1152/ajpendo.2001.281.5.E891</ArticleId></ArticleIdList></Reference><Reference><Citation>Kasarskis, E. J. et al. Estimating daily energy expenditure in individuals with amyotrophic lateral sclerosis. Am. J. Clin. Nutr. 99, 792&#x2013;803 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24522445</ArticleId><ArticleId IdType="pmc">3953880</ArticleId><ArticleId IdType="doi">10.3945/ajcn.113.069997</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimizu, T. et al. The measurement and estimation of total energy expenditure in Japanese patients with ALS: a doubly labelled water method study. Amyotroph. Lateral Scler. Frontotemporal Degener. 18, 37&#x2013;45 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">27892703</ArticleId><ArticleId IdType="doi">10.1080/21678421.2016.1245756</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopes da Silva, H. F. et al. Dietary intake and zinc status in amyotrophic lateral sclerosis patients. Nutr. Hosp. 34, 1361&#x2013;1367 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">29280652</ArticleId></ArticleIdList></Reference><Reference><Citation>Barros, A., Dourado, M. E. T. Jr., Pedrosa, L. F. C. &amp; Leite-Lais, L. Association of copper status with lipid profile and functional status in patients with amyotrophic lateral sclerosis. J. Nutr. Metab. 2018, 5678698 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30116640</ArticleId><ArticleId IdType="pmc">6079445</ArticleId><ArticleId IdType="doi">10.1155/2018/5678698</ArticleId></ArticleIdList></Reference><Reference><Citation>Chelstowska, B. &amp; Kuzma-Kozakiewicz, M. Biochemical parameters in determination of nutritional status in amyotrophic lateral sclerosis. Neurol. Sci. 41, 1115&#x2013;1124 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">31897946</ArticleId><ArticleId IdType="doi">10.1007/s10072-019-04201-x</ArticleId></ArticleIdList></Reference><Reference><Citation>Lemos, T. &amp; Gallagher, D. Current body composition measurement techniques. Curr. Opin. Endocrinol. Diabetes Obes. 24, 310&#x2013;314 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28696961</ArticleId><ArticleId IdType="pmc">5771660</ArticleId><ArticleId IdType="doi">10.1097/MED.0000000000000360</ArticleId></ArticleIdList></Reference><Reference><Citation>Keys, A., Brozek, J., Henschel, A., Mickelson, O. &amp; Taylor, H. L. The Biology of Human Starvation (University of Minnesota Press, 1950).</Citation></Reference><Reference><Citation>Park, J.-W. et al. Body fat percentage and availability of oral food intake: prognostic factors and implications for nutrition in amyotrophic lateral sclerosis. Nutrients 13, 3704 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34835960</ArticleId><ArticleId IdType="pmc">8622757</ArticleId><ArticleId IdType="doi">10.3390/nu13113704</ArticleId></ArticleIdList></Reference><Reference><Citation>University of Kentucky College of Medicine. ALS Nutrition Calculator. University of Kentucky College of Medicine https://alsnutrcalc.ukhc.org/calc (2023).</Citation></Reference><Reference><Citation>Sherman, M. S., Pillai, A., Jackson, A. &amp; Heiman-Patterson, T. Standard equations are not accurate in assessing resting energy expenditure in patients with amyotrophic lateral sclerosis. J. Parenter. Enter. Nutr. 28, 442&#x2013;446 (2004).</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0148607104028006442</ArticleId></ArticleIdList></Reference><Reference><Citation>Pontzer, H. et al. Daily energy expenditure through the human life course. Science 373, 808&#x2013;812 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34385400</ArticleId><ArticleId IdType="pmc">8370708</ArticleId><ArticleId IdType="doi">10.1126/science.abe5017</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>